Open Label Extension to Assess the Safety of Long-Term Treatment With Ampion for Severe Osteoarthritis (OA) of the Knee

Severe Osteoarthritis of the Knee Clinical Trial

Official title: An Open Label Extension Study to Assess the Safety of Long-Term Treatment With a 4 mL Intra-Articular Injection of Ampion in Adults With Pain Due to Severe Osteoarthritis of the Knee

Status Terminated

Clinical Trial Summary

This Open Label Extension (OLE) study will assess the safety of long-term treatment with a 4 mL intra-articular injection of Ampion™ in adults with pain due to severe osteoarthritis of the knee

Clinical Trial Description

An Open Label Extension (OLE) study will assess the safety of long-term treatment with a 4 mL intra-articular injection of Ampion™ in adults with pain due to severe osteoarthritis of the knee.

The primary trial objective was to evaluate the safety of a 4-mL intra-articular (IA) injection of Ampion with repeat dosing every 12 weeks for 52 weeks with five total injections of Ampion. ;

Related Conditions & MeSH terms

• Osteoarthritis
• Osteoarthritis, Knee
• Severe Osteoarthritis of the Knee

• NCT number: NCT03349645
• Study type: Interventional
• Source: Ampio Pharmaceuticals. Inc.
• Status: Terminated
• Phase: Phase 3
• Start date: December 8, 2017
• Completion date: October 4, 2018